Rebecca  Chambers net worth and biography

Rebecca Chambers Biography and Net Worth

Exec. VP & CFO of Veracyte
Rebecca Chambers has extensive healthcare leadership experience, previously serving as Chief Financial Officer for Outset Medical, a publicly traded medical technology company focused on reducing dialysis cost and complexity. While at Outset Medical, Ms. Chambers led the company through a new debt arrangement, Series E fundraising, IPO and multiple follow-on offerings. Prior to joining Outset, Ms. Chambers served in several financial roles at Illumina, including Vice President of Financial Planning and Analysis, Vice President of Investor Relations and Treasury, and Senior Director of Investor Relations. She has also served as head of Investor Relations and Corporate Communications at Myriad Genetics and held various roles in investor relations at Life Technologies. Earlier in her career, Ms. Chambers served as a Vice President at Bank of America and a Senior Research Associate at Millennium Pharmaceuticals (now part of Takeda Pharmaceuticals). Ms. Chambers serves on the board of Inari Medical, a medical device company focused on venous diseases. She holds a B.S. in Biology from John Carroll University and an M.B.A. from The S.C. Johnson Graduate School of Management at Cornell University.

How old is Rebecca Chambers?

Ms. Chambers is currently 45 years old. There are 5 older executives and no younger executives at Veracyte. The oldest executive at Veracyte is Dr. Phillip G. Febbo M.D., Chief Scientific & Medical Officer, who is 58 years old. Learn More on Rebecca Chambers' age.

How do I contact Rebecca Chambers?

The corporate mailing address for Ms. Chambers and other Veracyte executives is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. Veracyte can also be reached via phone at (650) 243-6300 and via email at [email protected]. Learn More on Rebecca Chambers' contact information.

Has Rebecca Chambers been buying or selling shares of Veracyte?

Rebecca Chambers has not been actively trading shares of Veracyte within the last three months. Learn More on Rebecca Chambers' trading history.

Who are Veracyte's active insiders?

Veracyte's insider roster includes Bonnie Anderson (Insider), Rebecca Chambers (Exec. VP & CFO ), Karin Eastham (Director), Jens Holstein (Director), Giulia Kennedy (Insider), and Marc Stapley (CEO & Director ). Learn More on Veracyte's active insiders.

Are insiders buying or selling shares of Veracyte?

In the last year, insiders at the biotechnology company sold shares 4 times. They sold a total of 27,432 shares worth more than $717,186.41. The most recent insider tranaction occured on April, 1st when Director Karin Eastham sold 10,000 shares worth more than $216,500.00. Insiders at Veracyte own 2.6% of the company. Learn More about insider trades at Veracyte.

Information on this page was last updated on 4/1/2024.

Rebecca Chambers Insider Trading History at Veracyte

See Full Table

Rebecca Chambers Buying and Selling Activity at Veracyte

This chart shows Ms. Rebecca Chambers's buying and selling at Veracyte by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Veracyte Company Overview

Veracyte logo
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $19.83
Low: $19.81
High: $20.70

50 Day Range

MA: $21.93
Low: $18.86
High: $25.53

2 Week Range

Now: $19.83
Low: $18.61
High: $30.52

Volume

563,798 shs

Average Volume

638,133 shs

Market Capitalization

$1.49 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.62